Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

JTO Clin Res Rep. 2020 Nov 1;1(4):100071. doi: 10.1016/j.jtocrr.2020.100071. Epub 2020 Jun 20.

Authors

Andrew J Piper-Vallillo¹, Brian T Halbert¹, Deepa Rangachari¹, Susumu S Kobayashi^{1

2}, Daniel B Costa¹

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.

No abstract available

Publication types

Case Reports

Grants and funding